Antiretroviral drugs (ARVs) are used to treat the human immunodeficiency virus (HIV), which causes acquired immune deficiency syndrome (AIDS). ARVs minimise the symptoms and viral load of HIV, especially if it is diagnosed and treated quickly. The HIV diagnostic test and antiretroviral therapy are free of charge in Brazil. Despite improvements brought about by ARVs in the quality of life and life expectancy of infected individuals, HIV/AIDS is still considered one of the most severe epidemics in the world. This is because of the absence of an effective preventive vaccine for the virus, which leads to constantly increasing numbers of infected people ([@B22]). Despite the high incidence of the disease, the mortality of AIDS is declining ([@B14]). Currently, although it is possible to live a normal life without symptoms of the disease through ARV treatment, it is still necessary to control viral dissemination owing to the absence of appropriate prophylaxis.

HIV has a high mutation rate, which can be correlated with the emergence of drug-resistant variants when viral replication is not sufficiently inhibited ([@B4]). This is why it is so difficult to develop efficient prophylactic methods and lasting treatments with the same class of drugs. In addition, HIV has significant genomic diversity, and recombination between different viral strains is quite common. This genetic variability creates a complex global pattern in the distribution of viral subtypes. In Brazil, the predominant genotype is B, followed by BF recombinants, and then F and C subtypes ([@B11]). However, since it is a large country, the distribution model of viral subtypes is distinct for each Brazilian region ([@B13], [@B12], [@B6], [@B8], [@B10], [@B2], [@B5]). In Bahia, which is the largest state in north-eastern Brazil, 26,268 cases of HIV infection had been catalogued by October 2015 ([@B21]). Previous studies conducted in the capital, Salvador ([@B10], [@B1], [@B18]), and in an inner city, Feira de Santana ([@B17], [@B11]), found that the prevalence of subtypes in this region was similar to the national distribution.

To better characterise the HIV/AIDS epidemic in Bahia, the present study used clinical and epidemiological data from HIV-1 infected individuals recruited between 2002 and 2012 to determine population and viral features. This analysis will contribute to the understanding and monitoring of the dissemination of HIV in this Brazilian region.

MATERIALS AND METHODS
=====================

Clinical, epidemiological, and molecular data generated in previous studies from our group in Salvador and Feira de Santana were collected and organised in a database. Thirty-two patient samples were obtained in the [@B10] study. From these, 32 *gag* sequences and 31 *env* sequences were included in the present study. Fifty-eight patient samples were obtained in the [@B1] study, from which 42 *gag* sequences and 40 *env* sequences were included in the present study. [@B18] collected 57 samples, and their *pol* sequences are included in this study. Thirty-nine of the individuals were analysed in both the Araujo and Santos studies. [@B11] analysed a cohort of 58 individuals (50 women and eight children), from which *pol* sequences were included in this work. Monteiro-Cunha et al. (unpublished observations) also studied a cohort of 97 patients aged 18 years or older who were HIV-1 positive and treatment-naïve, from which *pol* sequences were included in the present analysis. Patients received regular follow-up consultations at the Professor Edgard Santos University Hospital, or at the Specialised Centre for Diagnosis, Care and Research in AIDS, STDs and Viral Hepatitis (CEDAP), and signed a term of informed consent to participate in this study, which was approved by the Oswaldo Cruz Foundation (FIOCRUZ) Institutional Review Board (protocol number 376/2012). The blood samples were collected during 2012 and sent to the Laboratory of Haematology, Genetics and Computational Biology/IGM/FIOCRUZ for processing. Clinical and epidemiological data were obtained from patient medical records and interviews. Genomic DNA was extracted using a QIAamp DNA Blood Mini Kit (QIAGEN, Valencia, CA). Protease and reverse transcriptase (RT) regions of the *pol* gene were amplified and sequenced as previously described ([@B20]). The generated sequences are available in the GenBank database (https://www.ncbi.nlm.nih.gov/genbank/), under the accession numbers KT950963-KT951059.

Overall, the 263 HIV-1-seropositive patients who were analysed were recruited between 2002 and 2012 in Salvador and Feira de Santana. With around three million people, Salvador it is the largest city in the North-east Region and the 3rd-largest in the country, after São Paulo and Rio de Janeiro. Salvador also accounts for around 60% of the AIDS cases reported in Bahia ([@B21]). Feira de Santana is the second-most populous city in the state, with a population of around 600,000. It is located 100 km northwest of Salvador. Being a major junction of north-eastern Brazil's highways nearby, Feira de Santana functions as a crossroads for the traffic coming from the south and west-central portions of Brazil bound for Salvador and other important cities of the north-east. Therefore, Feira de Santana is now an important and diverse commercial and industrial centre of north-eastern Brazil ([Fig. 1](#f01){ref-type="fig"}) and is the city with the second largest number of AIDS cases in the state, accounting for nearly 7% of total AIDS cases ([@B21]).

Fig. 1: Salvador and Feira de Santana are the two most populous cities in Bahia state located in North-eastern Brazil.

All nucleotide sequences from *gag*, *pol*, and *env* were obtained by polymerase chain reaction (PCR) and direct sequencing of genomic DNA extracted from blood samples collected from the cohorts of previous studies. Sequences were aligned in fasta file format, using BioEdit software ([@B7]). The *gag*, *pol*, and *env* genomic regions analysed had nucleotide positions 896-1970, 2318-3161, and 6816-7668 relative to the HXB2 reference genome, respectively.

The viral subtype was confirmed using the HIV REGA subtyping tool (http://www.bioafrica.net/). Mutations associated with drug resistance were identified using the current version of the Stanford Database (STdb) program \[http://hivdb.stanford.edu/\] version 8.1.1, which was launched in September 2016 and presents an updated list of mutations.

GraphPad Prism (Version 7, GraphPad Software Inc., CA, USA) was used to perform statistical analysis by Fisher's exact test (two-tailed) to examine the significance of the association between two kinds of classification. P-values ≤ 0.05 were considered significant.

*Ethics* - The studies were approved by Oswaldo Cruz Foundation (FIOCRUZ) Ethics Committee and all the included individuals signed an agreement to participate at the study.

RESULTS
=======

This study analysed HIV gene sequences in 263 HIV-1-seropositive patients, out of which 74 samples had at least two sequenced regions (*gag* + *env*, *gag* + *pol*, *pol* + *env*, or *gag* + *env* + *pol*), and the other 189 had only one (*gag*, *env*, or *pol*). When more than one genomic region was available, the genotypes were combined to determine the final genotype.

The epidemiological and molecular characteristics of patients analysed in this study are shown in [Table I](#t1){ref-type="table"}. Following genotyping analysis, 179 (68.1%) samples were found to be subtype B, five (1.9%) were subtype C, and 23 (8.7%) were subtype F. The study also observed intergenic BF recombinant viruses in six (2.3%) individuals, intragenic (BFi) recombinants in 49 (18.6%) individuals, and DF recombination in one individual (0.4%). One hundred and twenty-nine (49.0%) individuals were adhering to a therapeutic regimen, whereas 118 (44.9%) were treatment-naïve. For 16 patients (6.1%) this information was not available. One hundred and thirty-two samples (50.2%) were obtained from women, 122 (46.4%) were obtained from men, and eight (3.0%) were from children of undetermined gender. One adult individual did not have available gender information. The ratio of male to female in this study was therefore 0.92:1. To correct for selection bias, we excluded the cohort comprised exclusively of women and children ([@B11]) from subsequent gender ratio calculations, which changed the total gender ratio to 1.47:1. The gender ratio for subtype B was 2.11:1, whereas the ratio for the group formed by F-related viruses (pure subtype F and BF recombinants) was 0.67:1. The age variation within this population and the transmission mode prevalence are shown in [Fig. 2A](#f02){ref-type="fig"}. The mean age was 36 years, and the range was 2-73 years. The main transmission mode was heterosexual contact, which was reported by 40.7% of the participants, followed by men who have sex with men (MSM) (19.0%) ([Fig. 2B](#f02){ref-type="fig"}). One hundred and forty-five patients did not have their clinical status defined, and from the remaining population of 118 individuals, 115 (97.5%) were asymptomatic, and three (2.5%) were symptomatic.

TABLE IClinical, molecular and epidemiological characteristics of human immunodeficiency virus (HIV)-1-infected individuals in Bahia stateCharacteristics (n = 263)Age (years)Minimum2Median36Mean36.5Maxim73Gender (%)Male122 (46.39%)Female132 (50.19%)Child08 (3.04%)NA01 (0.38%)Year of HIV-1 diagnosis1991 - 19968 (3.04%)1997 - 200120 (7.6%)2002 - 200620 (7.6%)2007 - 201285 (32.32%)NA130 (49.43%)Exposure categoryHeterosexual107 (40.68%)MSM50 (19.01%)Bisexual03 (1.14%)IDU06 (2.28%)Accident with needlestick03 (1.14%)Vertical12 (4.56%)Blood transfusion4 (1.52%)Others08 (3.04%)NA70 (26.62%)TreatmentTreated129 (49.05%)Naïve118 (44.87%)NA16 (6.08%)Clinical stateSymptomatic03 (1.14%)Asymptomatic115 (43.72%)NA145 (55.13%)GenotypeB179 (68.1%)BF06 (2.3%)BFi49 (18.6%)C05 (1.9%)DF01 (0.4%)F23 (8.7%)[^2]

Fig. 2: (A) characterisation of the human immunodeficiency virus (HIV)-1 infected population age group in Bahia state; (B) distribution of the transmission type in the HIV-1 infected population in the Bahia state.

The subtype prevalence was compared between the different populations included in the present work in order to investigate temporal trends in the subtype distribution ([Table II](#t2){ref-type="table"}). The earlier studies ([@B10], [@B1]) used the *env* and *gag* regions for subtyping. When comparing these two data sets, we observed an increase in the prevalence of pure subtypes B (84.0-91.8%) and F (2.3-4.9%) and a decrease in BF the prevalence of recombinants (13.1-3.3%) between 2002 and 2006. The most recent studies used the HIV *pol* regions for subtyping. When comparing the data from [@B18] who collected samples in 2006 with unpublished data from 2012, we observed a decrease in the prevalence of subtype B (77.2-73.2%) and in the prevalence of BF recombinants (21.0-8.3%) from 2006-2012 in Salvador city, while subtype F prevalence has increased (1.8-14.4%). These trends were similar when considering only the heterosexually infected individuals in these two populations.

TABLE IISubtype prevalence among infected individuals in Salvador and Feira de Santana (Bahia, Brazil) between 2002 and 2012Sampling year (publication)Subtype prevalence (%)BFCBFFD2002^*a,c*^ ([@B10])84%2,3% 13,1%0,6%2006^*a,c*^ ([@B1])91,8%4,9% 3,3% 2006^*b,c*^ ([@B18])77,2%1,8% 21% 2007^*b,d*^ ([@B11])67,2%6,9%1,724,1% 2012^*b,c*^ \[Monteiro-Cunha et al. (unpublished observations)\]73,2%14,4%4,18,3% [^3]

The protease and reverse transcriptase regions of the HIV *pol* gene in 212 patients were sequenced. One hundred and fifty-six sequences (73.6%) had subtype B, five (2.4%) had subtype C, and nineteen (9.0%) had subtype F. TBF recombination was observed in two (0.9%) samples and BFi was observed in 30 (14.2%) samples. ARV drug resistance mutations were then analysed for protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs).

A total of 196 (92.5%) viral strains were found to be susceptible to PIs, and from 16 sequences with mutations associated with any level of resistance to PIs, 12 (75.0%) were subtype B and four (25.0%) were subtype BFi. Four (25.0%) sequences had a major mutation to PI, whereas four (25.0%) had both major and minor mutations, and eight (50.0%) had only minor mutations. When considering only viruses that had major mutations, as recommended by the World Health Organization (WHO), the prevalence of mutations associated with resistance to PIs found in the cohort was 3.77% ([Table III](#t3){ref-type="table"}).

TABLE IIIComparison of human immunodeficiency virus (HIV) drug resistance prevalence in Bahia stateDrug Resistance[@B16] ^*a*^[@B11] ^*b*^[@B18] ^*c*^[@B19] ^*a*^Present study - ARV naïvePresent study - ARV experiencedN13258574711892NRTI9.8%15.5%24.6%10.6%0.85%20.65%NNRTI11.4%6.9%21.0%4.26%1.69%16.30%PI5%5.2%7.0%6.38%1.69%6.52%Total18.9%17.2%24.6%17%4.24%26.09%[^4]

One hundred and eighty-two (85.9%) isolates were susceptible to NRTIs, and from the 30 sequences harbouring mutations associated with any resistance level, 25 (83.3%) had genotype B, two (6.7%) had the recombinant genotype BFi, and three (10.0%) had genotype F. Out of these, 20 (66.7%) viruses had high or intermediate levels of resistance to NRTIs, and 10 (33.3%) had only low levels of resistance. Thus, the prevalence of mutations associated with intermediate and high level resistance to NRTIs in this population was 9.4% ([Table III](#t3){ref-type="table"}).

One hundred and seventy-eight (84.0%) strains were susceptible to NNRTIs. Out of the 34 viruses with mutations associated with any resistance level to NNRTIs, 27 (79.4%) were subtype B, three (8.8%) were subtype BFi, three (8.8%) were subtype F, and one (2.9%) was subtype C. For NNRTIs, 18 (52.9%) had a high or intermediate resistance level, and 16 (47.1%) had a low resistance level. Therefore, the prevalence of mutations associated with intermediate and high resistance level against NNRTIs in this cohort was 8.5% ([Table III](#t3){ref-type="table"}). Eighty percent of the mutated viruses were classified as subtype B.

Overall, 30 individuals (14.2%) had mutations associated with significant drug resistance. Eight individuals (3.7%) had resistance mutations for NRTI, seven (3.3%) for NNRTI, and three (1.4%) for PI. One (0.5%) patient had resistance mutations for PI and NRTI, seven (3.3%) for NRTI and NNRTI, and four (1.9%) individuals had resistance to all three drug classes. The most prevalent mutation associated with resistance to PIs was V82A (1.9%), conferring resistance to Indinavir (IDV) and Lopinavir (LPV). The mutation I54V (1.4%) showed susceptibility only for Darunavir (DRV), and L90M (1.4%) only for DRV and Tipranavir (TPV). The most prevalent mutation associated with resistance to NRTIs was M184V (6.1%), which conferred high resistance to Lamivudine (3TC) and Emtricitabine (FTC) drugs. The K70R mutation (3.3%) conferred resistance to Zidovudine (AZT). M41L (4.7%) combined with T215Y (2.4%) also had high resistance to AZT, but this also conferred intermediate to high resistance to Stavudine (D4T). Where the L210W mutation also appears in this set, it potentiates high resistance to AZT and d4T. If it appears alone, it appears to confer intermediate to high resistance against Abacavir (ABC) and Tenofovir (TDF). The most prevalent mutation associated with resistance to NNRTIs in this dataset was K103N (2.8%), followed by G190A (1.9%) and Y181C (1.4%). All of these mutations conferred high or intermediate resistance against Nevirapine (NVP) and Efavirenz (EFV), and the latter also conferred intermediate resistance to Etravirine (ETR) and Rilpivirine (RPV). The prevalence of the other mutations ranged from 0.05% to 0.09% ([Table IV](#t4){ref-type="table"}).

TABLE IVMolecular genotype and drug resistance profile of human immunodeficiency virus (HIV)-1-infected individuals living in Bahia stateCitySample IDSubtypeTreatmentNRTINNRTIPISSABAS011BYes K103N  BAS015BFiYesK70R, M184V   BAS048BYesM184V   BAS053BYesM184V   **BAS065** ^***a***^**BYesM41L, L210W, T215YY181CM46L, I54V, V82A** **BAS069** ^***a***^**BFiYesK70R, M184VL100I, K103EI54V, L90M** BAS075BFiYes K103N  **BAS087** ^***a***^**BYesM41L, L210W, T215YL100I, K103NM46L, I54V, V82A** BAS095BYesM41L, M184V, T215YK103S, G190A  BAS102BYesM41L, M184V, T215YY188L  **BAS111** ^***a***^**BYesK70R, T215FY188LI50V, I54L, V82A, L90M** BAS113BNA Y181C  BAS134BYesM41L, K70R, M184V, L210W, T215Y   BAS141BYesM41L, M184V, L210W   BA25MLS^b^BNo K103N  BA 91ISM^b^BNo  M46I, V82T BA111EGS^b^BFiNo G190A  BA114EGM^b^BNo  L90M BA115MSP^b^BNoK65N  FSABR100FSM145BYesK70R   BR145FSC100BYesM41L, M184VG190S  BR39FSBYes A98G  BR47FSBYesK70RK103N, Y181C, G190A  BR49FSFYesM41L, M184VK101E, G190A  BR51FSBYes  M46I, I50L, V82A BR52FSFYesM41L, M184VA98G  BR57FSBYesM41L, T69D   BR60FSBYesM184VK103N  BR85FSBYes L100V  BR91FSM83BYesK70R, M184V I54L, N88T[^5]

There was no statistically significant relationship between mutations and age, however it is important to note that the individual BR145FSC100 is a 9-year-old child ([Table IV](#t4){ref-type="table"}) with the mutations M41L, M184V e G190S, which in combination confer high levels of resistance to the drugs 3TC and FTC, intermediate levels of resistance to d4T and Didanosine (DDI) (in the NRTI group), and high levels of resistance to EFV and NVP (in the NNRTI group).

Out of the 30 individuals with high and intermediate ARV resistance mutations, five (16.7%) were drug-naïve. For all classes of ARVs, the prevalence of mutations conferring intermediate and high resistance levels were higher among patients under treatment (26.1%) than among drug-naïve individuals (4.2%) (p ≤ 0.001). Among 92 treated individuals that were characterised by genome sequences of the *pol* region, six (6.5%) had mutations conferring resistance against PIs, 19 (20.6%) against NRTIs, and 15 (16.3%) against NNRTIs. Among 118 drug-naïve individuals with resistance mutations, two (1.7%) had mutations conferring resistance against PIs, one (0.9%) against NRTIs, and two (1.7%) against NNRTIs.

DISCUSSION
==========

Brazil is a large country with diverse HIV-1 genotype patterns in its geographic regions. Bahia is the most populous state in the North-east Region, with the highest number of AIDS/HIV cases ([@B10]). The clinical, molecular, and epidemiological characterisation of the HIV-1-seropositive population is important to better understand the local epidemic. In this report, the *gag*, *pol*, and *env* sequences for each individual genomic region that had been obtained in previous studies were combined, allowing for the determination of a more reliable genotypic profile of the HIV-1 variants circulating in this area. As determined by these previous studies, and confirmed in the present study, it is clear that the B genotype is still predominant in Bahia ([@B10], [@B17], [@B18], [@B1], [@B11]).

The present study demonstrated that the age group with the highest HIV infection rate was 31-40 years. The epidemiological profile chart resembles a pyramid ([Fig. 2A](#f02){ref-type="fig"}), which verifies the pattern described by the Ministry of Health for the Brazilian infected population ([@B15]) and by the Bahia Secretariat of Health Surveillance (SOHS) for Bahia state population ([@B21]), both of which reported the majority of cases occurring in the age range of 31-40 years. It has previously been asserted that HIV is more prevalent in men than in women ([@B15]). Conversely, we determined that most HIV infections occur in females, with 50.2% of the population (ratio 0.92:1) infected. However, a cohort that only evaluates the mother-to-child transmission, with 50 women and eight children ([@B11]), was included in our meta-analysis and we thus excluded this cohort for gender analysis calculations. Among the remaining 205 patients, 122 (59.5%) were men. The male to female ratio in this group was 1.47:1, similar to that reported by the SOHS for the entire Bahia population, which was reported to be 1.5:1 between 2002 and 2012 ([@B21]).

The highest risk of exposure in this cohort was heterosexual contact (40.7%), followed by MSM (19.0%) ([Fig. 2B](#f02){ref-type="fig"}). The AIDS bulletin published by the SOHS reported that both heterosexual and homosexual contact were responsible for viral transmission (61.0% and 15.8% respectively) in the Bahia population from 2005 to 2014 ([@B21]). The differences between these rates and the rates observed in the present study might be because the exposure category was not informed by almost 30% of the population included in the present analysis ([Table I](#t1){ref-type="table"}). In addition, the results presented here may be biased owing to the fact that we included a cohort of women and children infected by vertical transmission. In fact, in the present study, a rate of 4.56% of vertical transmission was observed, whereas the data reported by the Secretariat indicates a rate of 0.8% in the period from 2005 to 2014.

The subtype B male/female ratio remains higher for men (1.23:1), and the opposite occurs for F subtype-related viruses (0.46:1). Furthermore, 76.8% of the individuals infected with either F or BF genotypes in this analysis were infected through heterosexual transmission. From another point of view, when the entirety of heterosexually infected individuals were analysed, we found that 40.2% carry the F or BF virus, whereas among individuals infected through another transmission path, only 16.7% carry the F or BF viral subtype (p \< 0.001). On the other hand, among individuals infected through homosexual contact, subtype B is predominant (86%) (p \< 0.01). These results indicate an association between heterosexual contact and the F viral subtype, whereas the transmission of the B subtype is associated with homosexual contact.

For all classes of drugs analysed, the prevalence of mutations associated with therapeutic resistance was higher among individuals under treatment (6.5% PIs, 20.65% NRTIs, NNRTIs 16.3%) than among the drug-naïve (PIs 1.7%, 0.9% NRTIs, NNRTIs 1.7%). [@B3] defined the mutational profile associated with ARV resistance in infected individuals from five different cities in Brazil, and concluded that DRV and TPV are the most susceptible drugs in the PI group in Salvador city, which was confirmed in the present study. We also verified that there was lower susceptibility to 3TC in the NRTI group, and to NVP and EFV in the NRTI group ([@B3]), with 3TC and EFV in combination with TDF used as the first line of treatment ([@B9]). Clinical relevance was also demonstrated for the individuals BAS065, BAS069, BAS087, and BAS111 ([Table IV](#t4){ref-type="table"}), who had high and intermediate levels of resistance to all drug classes (PI, NRTI and NNRTI) while under treatment. These observations reinforce the idea that ARV treatment may lead to eventual drug failure, once exposure drives high selective pressure to the acquisition of resistance ([@B3]).

We found a significantly lower prevalence (4.2%) of transmitted drug resistance (TDR) within the drug-naïve population during the 2006-2012 period, compared with previous studies concerning drug-naïve individuals in Bahia ([Table III](#t3){ref-type="table"}). [@B16] reported 18.9% TDR, whereas [@B19] reported 17% TDR (p ≤ 0.01). The prevalence of resistance to NRTIs was lowest in the untreated population (0.9%), which could perhaps indicate a low TDR. The NRTI resistance in this dataset was markedly lower than that observed by [@B16] (9.8%) and [@B19] (10.6%). On the other hand, the prevalence of drug resistance among ARV-treated individuals (26.09%) was similar to that found by [@B11] (17.2%) in Feira de Santana and by [@B18] (24.6%) in Salvador. This similarity is expected, since the current study includes samples from both previous studies, in which 82.8% and 77.2% of the analysed population were receiving antiretroviral treatment, respectively. The low prevalence of drug resistance among treated individuals might be related to the genomic origin of the analysed sequences. Significantly fewer mutations have been found in proviral DNA compared to historic viral RNA genotypes, which suggests that some resistance mutations are not archived or are not detectable in the latent reservoir ([@B23]). Moreover, out of 92 treated individuals, 42 (45.7%) had undetectable viral load, indicating that these individuals were not failing therapy. This observation, in addition to other unidentified inclusion bias, such as sample collection during treatment suppression and very low treatment adherence, could also contribute to the low resistance rate observed within this group. Among ARV-treated individuals, the NRTI resistance rate was always higher than that of other drug classes ([@B11], [@B18]), which was similarly observed in the drug-naïve cohort studied by [@B19]. Overall, these observations point to the need for better designed population studies to accurately determine the drug resistance prevalence in this area.

Only four (16.7%) out of 24 individuals with drug-resistance mutations had information regarding their drug regimen. BAS015 was being treated with AZT+3TC+IDV and had K70R and M184V mutations, which confer resistance to both AZT and 3TC. However, this patient presented viral suppression with undetectable viral load, which indicate the infection was under control by IDV. BA065 was being treated with AZT+3TC+EFV and had mutations ([Table IV](#t4){ref-type="table"}) that confer resistance to all three drugs included in their drug regimen, suggesting therapy failure. In fact, this patient had experienced virologic failure (3.4 × 10^5^ copies/mL). BA075 was being treated with AZT+RTV and presented the K103N mutation, which indicated that they had either been re-infected with a resistant variant or experienced a previous treatment combination. This patient had a high viral load (7.3 × 10^5^ copies/mL). BAS134 was being treated with D4T+ATV and had mutations ([Table IV](#t4){ref-type="table"}) that confer resistance to D4T but not to ATV. Nonetheless, this patient had a viral load of 9.1 × 10^3^ copies/mL. Overall, these findings reinforce the importance of HIV genotyping for better clinical management of patients experiencing therapy failure.

The HIV epidemic in Bahia state has a high diversity of viral genotypes, but subtype B has the highest prevalence in the population as well as in the ARV-resistant population. This work highlights the importance of characterising the population ARV drug-resistance profile, highlighting important clinical cases. Through this report, it will be possible to better understand how HIV is circulating in the local population and thus develop new strategies to better manage the epidemic.
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